scispace - formally typeset
A

Arjun Kalvala

Researcher at Ohio State University

Publications -  11
Citations -  157

Arjun Kalvala is an academic researcher from Ohio State University. The author has contributed to research in topics: Mitochondrial ROS & Venetoclax. The author has an hindex of 7, co-authored 11 publications receiving 114 citations. Previous affiliations of Arjun Kalvala include International Centre for Genetic Engineering and Biotechnology & City of Hope National Medical Center.

Papers
More filters
Journal ArticleDOI

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

TL;DR: An undiscovered mechanism underlying synergistic effect of decitabine and venetoclax in AML cells is demonstrated, elucidating for impressive results in antileukemic activity against AML in preclinical and early clinical studies by combined treatment of these drugs.
Journal ArticleDOI

Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer

TL;DR: A subset of lung cancer patients are likely to be more susceptible to DNA cross-link based therapy, or to treatments in which additional repair mechanisms are targeted, given that FA pathway plays essential roles in response to DNA damage.
Journal ArticleDOI

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS

TL;DR: It is demonstrated that CD4+ T cells when incubated with tumor-derived exosomes from mutant (MT) KRAS non-small-cell lung cancer (NSCLC) cells, patient sera, or a mouse xenograft model, induce phenotypic conversion to FOXP3+ Treg-like cells that are immune-suppressive.
Journal ArticleDOI

Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.

TL;DR: The results demonstrate the potent preclinical antileukemic activity of ARTS as well as its potential for a rapid transition to a clinical trial either alone or in combination with conventional chemotherapy or BCL-2 inhibitor, for treatment of AML.
Journal ArticleDOI

Enhancement of gene targeting in human cells by intranuclear permeation of the Saccharomyces cerevisiae Rad52 protein

TL;DR: The yRad52tat11 fusion protein could be instrumental to increase GT in human cells and a ‘protein delivery approach’ offers a new tool for developing novel strategies for genome modification and gene therapy applications.